Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-12-11-Speech-2-164"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20071211.32.2-164"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"The subject of innovative medicines is particularly close to my heart, because I am actively involved in Poland with helping children suffering from rare genetic diseases. Unfortunately, these children are not covered by any health insurance programmes, and the medicines they require are too expensive. In most European countries, the cost of the medicines needed to keep such children alive and give them the opportunity to live near-normal lives is refunded.
As a Member of the European Parliament, I realise how important a European approach to the whole issue of medicines is. I refer to innovation, Union support for research and for scientists, and also to Union encouragement of pharmaceutical concerns, urging them to develop new medicines. In my opinion, the report by Mrs Grossetête is very important indeed.
I agree that the Union must change to a new and more effective method of managing research and innovation aimed at promoting the economic development of our continent, bringing relief to our citizens and even saving their lives in some cases. The European Commission's proposal to create joint technology initiatives will harmonise and simplify project financing.
With regard to research programmes on innovative medicines, it is important to involve SMEs, universities, patients, hospitals and the pharmaceutical industry, to ensure that medicines are safer, cheaper and more readily available. The public-private partnerships proposed by the Commission are therefore an excellent solution. They represent a new option for the pharmaceutical research sector."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples